The following is a summary of White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA published June 2022 in Frontiers in Allergy.
Atopic Dermatitis (AD)
AD, sometimes referred to as eczema, can cause frequent dry, scaly skin and red or dark rashes that cause intense, persistent itching. As many as one in ten people worldwide have AD, making it one of the most common long-term conditions.1-3
Asthma
Asthma is a disease associated with chronic airway inflammation that makes it difficult to breathe.4 Some asthma cases are classified as severe and can be harder to control, impacting daily life.4 Globally, more than 339 million people live with asthma.5
Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
People with CRSwNP, often called nasal polyps, have non-cancerous growths in their sinuses that lead to frequent runny noses, difficulty breathing, facial pain and congestion. While the number of people who have CRSwNP globally is not well documented, more than 900,000 people in the European Union and the United States live with CRSwNP.6
Understanding the underlying cause: type 2 inflammation
Type 2 inflammation is a specific type of immune response.7 Its normal function is to eliminate infection, however, when it does not work correctly it causes inflammation that can harm healthy tissue and is linked to allergic and atopic diseases.7,8,9
Globally, the occurrence of type 2 inflammatory diseases is increasing with CRSwNP, asthma and AD currently affecting up to 3%, 18% and 10% of the population respectively.4,10,11 For some people, type 2 inflammation can be the cause of more than one condition at the same time. This is known as a co-existing condition. People with CRSwNP, asthma and AD frequently have co-existing type 2 inflammatory diseases; for example, asthma also occurs in up to 65% of people with CRSwNP and in almost 50% of people with AD.12,13,14
Although several studies have investigated the unmet needs of people living with each disease individually, little is known about the experiences and needs of people who live with co-existing type 2 inflammatory diseases.
The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) – an organization focused on preventing and reducing the burden of allergies and airway diseases through the implementation of optimal care – set out to better understand the common needs of people living with more than one type 2 inflammatory disease.
Methodology
Seven university centers in seven European countries (Belgium, The Netherlands, United Kingdom, Greece, Switzerland, Germany and Denmark) agreed to have patients participate in interviews with EUFOREA about living with more than one type 2 inflammatory disease.
The analysis consisted of 70 interviews including 28 people initially diagnosed with CRSwNP, 21 people initially diagnosed with asthma and 21 people initially diagnosed with AD.
Barriers to care
The results of the interviews revealed that participants with asthma, AD and CRSwNP experienced similar barriers in their disease journey including impacts to their quality of life, treatment dissatisfaction and the need for coordinated care. Overall, specific perceived unmet needs overlapped between all three diseases, but unique needs exist for each condition as well.

Image adapted from reference 15
Call to action
Participants also provided similar suggestions and proposed solutions to the shortcomings in their care. Education for patients and healthcare providers was one of the most common recurring themes.
Along with education and awareness efforts, the participants asked for clear guidelines and consistent treatment strategies among different specialists and even among different countries.
Regarding the health care system, they also requested that politicians reach a unified and straightforward agreement on reimbursement and availability of care for type 2 inflammatory diseases in Europe.
An overview of the key shortcomings and suggestions:

Image adapted from reference 15
With these insights and recommendations, EUFOREA aims to help improve care pathways and increase awareness of type 2 inflammatory diseases with physicians, the academic community and health policy makers.
Take your own action! If you or someone you know has one or more of these diseases, it’s important to be your own advocate throughout your care journey. Be empowered! Ask your doctor about the underlying cause of your disease or diseases to ensure you are receiving the best care possible.
REFERENCES
¹Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016; 15(1): 35-50
²Gandhi NA, Pirozzi G, Graham NM. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert review of clinical immunology. 2017 May 4;13(5):425-37.
³Cherwinski, H. M., Schumacher, J. H., Brown, K. D., & Mosmann, T. R. (1987). Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. The Journal of experimental medicine, 166(5), 1229-1244
⁴Snapper CM, Finkelman FD, Paul WE. Regulatiopn of IgG1 and IgE production by interleukin 4. Immunological reviews. 1988 Apr 1;102(1):51-75.
⁵Mosmann, T. R. & Coffman, R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
⁶Ray, Anuradha, Timothy B. Oriss, and Sally E. Wenzel. “Emerging molecular phenotypes of asthma.” American Journal of Physiology-Lung Cellular and Molecular Physiology 308.2 (2015): L130-L140.
⁷Muraro, Antonella, et al. “Precision medicine in patients with allergic diseases: airway diseas and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology.” Journal of allergy and clinical immunology 137.5 (2016): 1347-1358.
⁸Matsusaka, Masako, et al. “Subphenotypes of type 2 severe asthma in adults.” The Journal of Allergy and Clinical Immunology: In Practice 6.1 (2018): 274-276.
⁹Khan, Asif et al. “Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis.” European Respiratory Journal 2020; 56: Suppl. 64, 232.
¹⁰Silverberg, Jonathan I. Comorbidities and the impact of atopic dermatitis. Annals of Allergy, Asthma & Immunology. 2019.
¹¹Bieber T. Mechanisms of disease: atopic dermatitis. N Engl J Med. 2008; 358:1483-9.
¹²Gittler, J. K. et al. (2012). Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. The Journal of allergy and clinical immunology, 130(6), 1344-1354.
¹³Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. Journal of Allergy and clinical Immunology. 2007 Dec 1;120(6):1269-75.
¹⁴Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Anselmo-Lima WT. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:I-+.
¹⁵Huang E, Ong PY. Severe atopic dermatitis in children. Current allergy and asthma reports. 2018 Jun;18(6):1-8.
¹⁶von Mutius E. The burden of childhood asthma. Archives of disease in childhood. 2000; 82(suppl 2):ii2-ii5.
¹⁷Menard-Katcher P, Marks KL, Liacouras CA, Spergel JM, Yang YX, Falk GW. The natural history of eosinophilic oesophagitis in the transition from childhood to adulthood. Alimentary pharmacology & therapeutics. 2013
Jan;37(1):114-21.
¹⁸Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226-232.
¹⁹Sanz de Burgoa V, Rejas J, Ojeda P. Self-perceived sleep quality and quantity in adult subjects with asthma: Findings from the CosteAsma study. J Investig Allergol Clin Immunol. 2016;25(4).
²⁰Lucendo AJ, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335-358.
²¹Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2022. Available at:
https://ginasthma.org/gina-reports/ . Accessed: July 2022
²²Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, Chamlin SL, Cohen DE, Cordoro KM, Davis DM, Feldman SR. Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. Journal of the American Academy of Dermatology. 2014 Dec 1;71(6):1218-33.
²³European Respiratory Society. European Lung White Book, Chapter 2: The economic burden of lung disease. Available at: https://www.ershwhitebook.org/chapters/the-economic-burden-of-lung-disease/ . Accessed: June 2021.
²⁴Eckert L, Gupta S, Gadkari A, Mahajan P, Gelfand JM. Burden of illness in adults with atopic dermatitis: Analysis of National Health and Welness Survey data from France, Germany, Italy, Spain, and the United Kingdom. J Am Acad Dermatol. 2019;81(1):187-195.
²⁵Mukkada V, et al. Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16(4):]495-503.
²⁶Milton B et al. The social and economic consequences of childhood asthma across the lifecourse: a systematic review. Child: care, health and development. 2004 Nov;30(6):711-28.
²⁷Daugherty, Jonas, et al. “The impact of long-term systemic glucocorticoid use in severe asthma: a UK retrospective cohort analysis.” Journal of Asthma 55.6 (2018): 651-658.
²⁸Hirano I, Chan ES, Rank MA, Sharaf RN, Stollman NH, Stukus DR, Wang K, Greenhawt M, Falck-Ytter YT, Chachu KA, Day L. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020 May 1;158(6):1776-86.
²⁹Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology. 2014 Aug 1;71(2):327-49.
³⁰Menzies-Gow A, Canonica GW, Winders TA, de Sousa JC, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Advances in therapy. 2018 Oct;35(10):1485-96.
³¹Staikuniene J, et al. Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. Medicina (Kaunas) 2008; 44(4):257-265.
³²Liu, Jing Nan, et al. The prevalence of serum specific IgE to superantigens in asthma and allergic rhinitis patients. Allergy, Asthma & Immunology Research. 2014;6(3):263-266.
³³Schleimer, Robert P., and Sergejs Berdnikovs. Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases. Journal of Allergy and Clinical Immunology. 2017;139(6):1752-1761.
³⁴Sugita K, Kabashima K. Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. Journal of leukocyte biology. 2020 May;107(5):749-62.
³⁵Eichenfield, Lawrence F., et al. “Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.” Journal of the American Academy of Dermatology 70.2 (2014): 338-351
³⁶National Institutes of Health (NIH). Health Topics: Atopic Dermatitis. Available at: https://www.niams.nih.gov/health-topics/atopic-dermatitis. Last accessed June 2021.
³⁷Nordin S, Hedén Blomqvist E, Olsson P, Stjärne P, Ehnhage A, NAF2S2 Study Group. Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthma. Acta oto-laryngologica. 2011 Aug 1;131(8):826-32.
³⁸Wang R, Hirano I, Doerfler B, Zalewski A, Gonsalves N, Taft T. Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis. Digestive diseases and sciences. 2018 Jul;63(7):1756-62.
³⁹Prussin C, Lee J, Foster B. Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5- TH2 responses. Journal of allergy and clinical immunology. 2009 Dec 1;124(6):1326-32.
⁴⁰Mayo Clinic. Peanut Allergy. Available at: https://www.mayoclinic.org/diseases-conditions/peanut-allergy/symptoms-causes/syc-20376175. Accessed June 2021.
⁴¹Seys, Sven F., et al. “Cluster analysis of sputum cytokine-high profiles reveals diversity in T (h) 2-high asthma patients.” Respiratory research 18.1 (2017): 1-10.
⁴²Jackson DJ, Aljamil N, Roxas C, et al. The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? Thorax. 2018;73(suppl 4):A124-A125
⁴³M. Suárez-Fariñas, N. Dhingra and J. Gittler, “Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 132, no. 2, pp. 361-70, 2013.
⁴⁴M. Chaaban, E. M. Walsh and B. A. Woodworth, “Epidemiology and differential diagnosis of nasal polyps.,” American Journal of Rhinology & Allergy, vol. 27, no. 6, pp. 473-478, 2013.
⁴⁵Chehade M, et al. Phenotypic Characterization of Eosinophilic Esophagitis in a Large Multicenter Patient Population from the Consortium for Food Allergy Research. J Allergy Clin Immunol Pract. 2018;6(5):1534-1544.
⁴⁶Pereira MP, et al. Chronic nodular prurigo: clinical profile and burden. A European cross‐sectional study. [published online ahead of print, 2020 Feb 20]. J Eur Acad Dermatol Venereol. 2020.
⁴⁷Zeidler C, et al. Chronic prurigo of nodular type: a review. Acta Derm Venereol. 2018;98(2):173-179.
⁴⁸Pereira MP, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology
LEGAL DISCLAIMER
LEGAL NOTICE
This website (“Website”) is provided to you under these “Terms of Use” and any amendments or supplements to them (collectively referred to as this “Agreement”) that may be posted by Genzyme Corporation or one of its affiliated companies (collectively, “Site Owner,” “we”, “us”) from time to time. Your use of this Website, or any other services or content provided through the Website shall be deemed to constitute your consent to be legally bound by the terms and conditions of the Agreement, which shall be enforceable in the same way as if you had signed the Agreement. If you are not willing to accept the terms and conditions in the Agreement, we ask that you not access or use the Website.
WEBSITE INTEDED AUDIENCE
This Website is available to adults globally.
INFORMATION DISCLAIMER
This website, including any advice and recommendations on the Website, is intended solely as a general educational aid to raise awareness about certain type 2 inflammatory diseases.
The information on this Website is not intended as medical or healthcare advice, or to be used for medical diagnosis or treatment, for any individual problem. It is also not intended as a substitute for professional advice and services from a qualified healthcare provider familiar with your unique facts. Always seek the advice of your doctor or other qualified healthcare provider regarding any medical condition and before starting any new treatment. Your use of the site is subject to the additional disclaimers and caveats that may appear throughout the Website.
We assume no responsibility for any consequence relating directly or indirectly to any action or inaction you take based on the information, services, or other material on the Website. While we strive to keep the information on the Website accurate, complete, and up-to-date, we do no give any assurances, and will not be responsible for, any damage or loss related to the accuracy, completeness, or timeliness of the information on the Website.
OWNERSHIP
You understand that the Website is available for your personal, non-commercial use only. You agree that the Website is the property of the Site Owner; including all intellectual property rights in it and that you have no right to use them other than as set out in these Terms of Use. We are not responsible for any harm or loss that you suffer in relation to any use you make of the Website for any business purposes or other purposes not authorized under these Terms of Use. We reserve the right to refuse or terminate access to the Website at our discretion. The Website are provided free of charge and on that basis we have no obligation to provide any maintenance or support services in relation to them and we are not responsible for any loss or damage you may suffer as a result of any failure to maintain or update the Website.
You may not copy, change or ruse the Website, any updates to them or any part of them including the software incorporated in them.
You may use this Website only for lawful purposes and in accordance with these Terms of Use. You are granted a nonexclusive, nontransferable, revocable, limited license to view, print and distribute content retrieved from the Website for your personal, noncommercial purposes, provided that you do not remove or obscure the copyright notice or other notices displayed on the content. You may not copy, reprint, modify, display, perform, translate, distribute, adapt, broadcast, communicate to the public by telecommunication, circulate, or sell the content retrieved from the Website in any way, for any commercial use or provide it to any commercial source, including other websites, without the prior written permission of Site Owner.
In addition, you agree not to:
1. use this Website in any manner that could disable, overburden, damage, or impair this Website, or interfere with any other use of this Website, including, any user’s ability to engage in real-time activities through this Website;
2. use any robot, spider or other automatic device, process or means to access this Website for any purpose, including to scrape, date mine, monitor or copy any of the material on this Website;
3. use any manual process to monitor or copy any of the material on this Website, or to engage in any other unauthorized purpose without the express prior written consent of Site Owner;
4. otherwise use any device, software or routine that interferes with the proper working of this Website; or
5. other attempt to interfere with the proper working of this Website.
We reserve all rights not expressly granted to you.
PRIVACY AND CONSENT TO USE DATA
The information that we obtain through your use of the Website is subject to our Privacy Policy (the privacy policy can be accessed by clicking the appropriate tab found here). Our Privacy Policy addresses our collection and use of the data you provide to us, including your rights relative to that information.
To the extent personal data is obtained through the website, Genzyme Corporation is data controller for the processing of that personal data.
Genzyme Corporation:
50 Binney Street,
Cambridge, Massachusetts 02142
Tel.: +1 (617) 252-7500
SITE HOSTING
Microsoft Nederland B.V. Evert van de Beekstraat 354
1118 CZ Schiphol (Amsterdam) The Netherlands
ELECTRONIC COMMUNICATIONS
The information communicated on the Website constitutes an electronic communication. When you communicate with us through the Website or via other forms of electronic media, such as e-mail, you are communicating with us electronically. You agree that we may communicate electronically, subject to local privacy laws, and that such communications, as well as notices, disclosures, agreements, and other communications that we provide to you electronically, are equivalent to communications in writing and shall have the same force and effect as if they were in writing and signed by the party sending the communication.
DISCLAIMER OF WARRANTIES WITH RESPECT TO USE OF WEBSITE
The Website is provided on an “as is” and “as available” basis. Except as specifically provided herein, to the fullest extent permissible pursuant to applicable, Site Owner expressly disclaims all warranties of any kind, whether express, legal or implied, including, without limitation, any warranties of merchantability, fitness for a particular purpose and non-infringement.
Site owner does not make any warranty that the Website will meet your requirements, or that access to the Website will be uninterrupted, timely, secure, or error-free, or that defects, if any, will be corrected. Site owner makes no warranties as to the results that may be obtained from the use of the Website or as to the accuracy, quality, or reliability of any information obtained through the website.
You understand and agree that any material and/or data downloaded or otherwise obtained through the use of the Website is used at your own risk and that you will be solely responsible for any damage to your computer system or loss of data that results from the download of such material and/or data.
No advice or information, whether oral or written, obtained by you from Site Owner or through the Website shall create any warranty not expressly made herein.
LIMITATIONS OF LIABILTY
You expressly understand agree that under no circumstances will Site Owner, its affiliates and any of their respective directors, officers, employees, agents, mandataries or other representatives be liable for direct, indirect, special, incidental, consequential, punitive or aggravated damages, including, without limitiation, any loss of use, loss of income, saving or profits, loss of data, loss of goodwill, cost of procurement of substitute services, or any other indirect, special, incidental, or consequential damages, howsoever caused, and on any theory of liability, whether for breach of contract, tort (including negligence and strict liability), or otherwise resulting from (1) the use of, or the inability to use, the Website; (2) the cost of procurement of substitute services, items, or websites; (3) unauthorized access to or alteration of your transmission or data (including personal information); (4) the statements or conduct of any third party on the Website; or (5) any other matter relating to the Website. These limitations will apply whether or not Site Owner has been advised of the possibility of such damages and notwithstanding any failure of essential purpose of any limited remedy. This exclusion of liability shall apply to the fullest extent permitted by applicable laws.
TRADEMARK NOTICES
The trademarks and brand names displayed on this Website are the property of Site Owner, its affiliates or third party owners. You may use or display any trademarks or service marks owned by Site Owner without our prior written consent. You may not use or display any other trademarks or service marks displayed on this Website without the permission of their owners.
MODIFICATION OR SUSPENSION OF THE WEBSITE
We will make reasonable efforts to make the Website available but we may from time to time need to interrupt, restrict, modify or discontinue, temporarily or permanently the Website or parts of it without notice. We will not be responsible for any harm or loss you may suffer as a result of such actions.
TERMINATION
We may at any time terminate your use of or access to the Website if we have a good reason to do so which includes any breach by you of these Terms of Use and any other relevant guidelines. We will not be responsible for any loss or harm you may suffer as a result of termination of your use of the Website in these circumstances. In the event of any termination you must stop using the Website and you agree that the provisions of the Agreement regarding Ownership, Trademark Notices, Indemnification, Disclaimer or Warranties, Limitations of Liability, and Applicable Law shall survive any such termination.
LINKS TO THIRD PARTY SITES
This Website may contain links or references to third party websites. These links are provided for your convenience only. No endorsement of any third party products, services or information is expressed or implied by any information, material or content of any third party contained in, referred to, included on, or linked from or to this Website. Any information, data, opinions, recommendations, products or services provided by such third parties and not of Site Owner. Your use of such third party websites is subject to the terms of use and the privacy policies of such websites.
INDEMNIFICATION
You agree to indemnify and hold harmless Site Owner and its affiliates and their respective directors, officers, employees, agents, or other representatives from and against all claims, liability, damages and expenses, including without limitation all legal fees and costs arising from or relating to (a) your breach of these Terms of Use; (b) your use of this Website including without limitation transmission or placement of information or material by you on this Website; and (c) any claim or allegation that any of your User Content infringes the intellectual property or other proprietary rights, or privacy rights, of any third party.
MODIFICATIONS TO THESE TERMS
We may make changes to the Terms of Use from time to time in our sole discretion, by updating these Terms of Use on this Website, and specifying the effective date of the new version of the Terms of Use. The “Last Modified” date at the top of these Terms of Use will indicate when the latest changes were made. Your continued use of the Website following the posting of a new version of the Terms of Use constitutes your acceptance of any such changes. Accordingly, whenever you visit this Website, you should check to see if a new version of the Agreement has been posted.
CONTACT INFORMATION
If you have any questions or concerns with respect to these Terms of Use or the Website you may contact us as is identified in the Contact Us section of this Website.
SEVERABILITY OF AGREEMENT
Should any part of provision of these Terms of Use be held unlawful, void, invalid, or unenforceable that portion shall be deemed severable from these Terms of Use and shall not affect the validity and enforceability of any remaining provisions.
SURVIVAL
All Sections shall survive the termination of the right to use the Website.
APPLICABLE LAW AND JURISDICTION
The information on the Website is intended for audiences globally. The Agreement and the resolution of any dispute related to the Agreement, the Website, or items you purchase through the Website, and any non-contractual obligations arising out of or in connection with these Terms of Use, shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts in the United States of America and you agree to submit to the personal and exclusive jurisdiction of such courts.
Privacy Policy and Cookies
WHY THIS DOCUMENT?
As part of its day-to-day operation, SANOFI provides access to a variety of tools and resources which are destined to provide information to all the individuals with whom it has business interactions with (patients and their relatives, participants to clinical trials, healthcare professionals, users of products and services, workers, etc.) regarding its activities.
Such tools and resources may be provided in various formats, including, more specifically in electronic format and by means of online electronic communications, including the website available at www.sanofi.com and any other website made available by SANOFI and to which this policy applies (hereinafter together the “Website”). In order to be able to provide them, SANOFI is fully committed to the protection of Personal Data and intends to provide you with all relevant information regarding the way in which SANOFI processes your Personal Data on the Website.
You will therefore find below all relevant information regarding the processing of Personal Data conducted on this Website. Please note that the content of this Website Privacy Policy may change from time to time, for instance in case of evolution of our processes or as a result of applicable law. Should these changes be objectively substantial and affect your rights or our obligations pertaining to the protection of Your Personal Data (and insofar as we have a means to contact you), we will notify you of the update by adequate means based on the information we may have collected.
However, we advise you to visit the page of this Website Privacy Policy regularly to verify any updates.
WHO IS RESPONSIBLE FOR THE PROCESSING OF PERSONAL DATA ON THIS WEBSITE (THE CONTROLLER)?
Genzyme Corporation is responsible for the processing of Personal Data of individuals using this website and therefore acts as the Controller:
Genzyme Corporation
50 Binney Street,
Cambridge, Massachusetts 02142
Tel.: + 1 (617) 252-7500
REMINDER: WHAT IS PERSONAL DATA & PROCESSING?
For the purposes of this Website Privacy Policy, Personal Data is any information relating to an identified or identifiable natural person, for all data processing carried out in the framework of its business and activities
- To make things clear, it is any information that relates to an individual. Such Personal Data can take the form of:
- Basic identification information such as your name or date of birth;
- Information that can be attributed to you directly or indirectly – such as a post on a social media;
- Information which can be associated to you or your device such as, for instance, an IP address (i.e. the network address of your machine);
- Etc.
In this respect, the notion of “processing” designates any action that is undertaken on your Personal Data such as, for instance:
- Collection;
- Storage;
- Access;
- Analysis;
- Deletion;
- Etc.
WHAT PERSONAL DATA DOES THIS WEBSITE COLLECT?
When operating, this Website may collect the following categories of Personal Data:
- Connection data: any information regarding your connection and access to this Website (e.g. type of machine and browser used, timestamp of your connection, IP address, pages visited, etc.), browsing history
- Location data: information that may be provided by your machine and browser about your location if you allow such information to be shared with Sanofi
- Data relating to and data which may be collected by cookies: for more information about cookies, please click here to view our cookies policy (the cookies policy can be accessed by clicking the appropriate tab found here.)
In addition, this website embeds poll functionality which asks survey questions regarding health conditions. The responses to the survey questions are collected anonymously and aggregated with other responses in order to show collective results. The poll is multiple-choice with no option for free text.
FOR WHAT PURPOSES DOES THIS WEBSITE COLLECT PERSONAL DATA?
Any processing of Personal Data must be implemented for a defined purpose. In this respect, the collection and processing of Personal Data on this Website is conducted for the following purposes:
- To personalize your browsing experience: when using our services; ensure that our services are presented in the way the best suits you; understand your professional and personal interests in our content, product and services or other content and adapt our content to your needs and preferences; present you products and offers tailored to you.
- To improve our products and services: identify usage trends and develop new products and services; understand how you and your device interacts with our services; track and respond to safety concerns; determine the effectiveness of our promotional campaigns, conduct surveys.
ON WHAT GROUNDS DOES THIS WEBSITE PROCESS YOUR PERSONAL DATA?
For the purposes of this Website, your Personal Data is only processed on the basis of:
- your prior CONSENT: where you have clearly expressed your approval of SANOFI’s processing of your Personal Data. In practice, this will generally mean that SANOFI will ask you to sign a document, or to fill-in an online “opt-in” form or to follow any relevant procedure to allow you to be fully informed and then either clearly accept or refuse the envisaged Personal DATA processing. By navigating this Website and, if relevant, consenting to the processing of your Personal Data using cookies (as per our cookies policy).
- A contractual relationship between you and SANOFI: in such case, the processing of your Personal DATA is generally necessary to the execution or the performance of the contract; this means that if you do not wish SANOFI to process your Personal Data in that context, SANOFI may or will be obliged to refuse to enter into such contract with you or will not be able to provide the products or services covered in this contract.
- The “legitimate interest” of SANOFI in the sense of applicable data protection law. In such a case, SANOFI shall consider your fundamental rights and interests in determining whether the processing is legitimate and lawful.
HOW LONG IS THE PERSONAL DATA COLLECTED ON THIS WEBSITE RETAINED?
The Personal Data collected on this Website will be retained for the following periods, depending on the categories of Personal Data processed
- Connection data: Session duration
- Location data: Two years
- data relating to and data which may be collected by cookies: Please see the cookies policy. The cookies policy can be accessed by clicking the appropriate tab found here
WHO HAS ACCESS TO PERSONAL DATA
SANOFI may transfer your Personal Data both internally (i.e. to other SANOFI entities) and/or externally to third party service providers for the purposes outlined above.
Where such internal or external transfer of Personal Data implies the transfer of your Personal Data to a country providing a lower level of protection to Personal Data than generally afforded in your jurisdiction, SANOFI will ensure that a sufficient level of protection is provided to your Personal Data by implementing adequate safeguards such as the European Standard Contractual Clauses, the SANOFI Binding Corporate Rules or asking for your prior explicit consent.
YOUR RIGHTS: SANOFI WILL ENSURE THAT YOU CAN EXERCISE YOUR RIGHTS PERTAINING TO YOUR PERSONAL DATA
You can exercise your rights as provided by applicable data protection laws.
To that end, SANOFI informs you that you are entitled:
- to have access upon simple request to your Personal Data- in which case you may receive a copy of such data (if requested), unless such data is made directly available to you, for instance within your personal account;
- to obtain a rectification of your Personal Data should your Personal Data be inaccurate, incomplete or obsolete;
- to obtain the deletion of your Personal Data in the situations set forth by applicable data protection law (‘right to be forgotten’);
- to withdraw your consent to the processing of Persona Data processing without affecting the lawfulness of processing, where your Personal Data has been collected and processed on the basis of your consent;
- to object to the processing of your Personal Data, where your Personal Data has been collected and processed on the basis of legitimate interests of SANOFI, in which case you will need to justify your request by explaining to us your particular situation;
- to request a limitation of the processing of Personal Data processing in the situations set forth by applicable data protection law;
- to receive your Personal Data for transmission from SANOFI to a third-party or to have your Personal Data directly transferred by SANOFI to the third-party of your choice, where technically feasible (data portability right allowed only where the processing is based on your consent)
if you would like to exercise any of these rights, please contact us as described in the “How to Contact Us” section below and we will take necessary steps to respond as soon as possible.
You may also file a complaint before a competent data protection authority regarding the processing of your Personal Data. While we suggest that you contact us beforehand, if you wish to exercise this right, you shoud contact directly the competent data protection authority.
HOW TO CONTACT US
SANOFI welcomes any questions or comments you may have regarding this Website Privacy Policy or its implementation. You can send any request pertaining to SANOFI’s use of your Personal Data to our Data Protection Officer at the following email address: privacy-office-global@sanofi.com.